GLP-1 Peptide Atlas, by Delfa

CompletedPhase 4

The Effect of a Liraglutide on IVF in Obese PCOS

The Effect of Liraglutide on Pregnancy Rates in Obese Women With PCOS Undergoing in Vitro Fertilization: a Pilot Randomized Study

Lead sponsor

University Medical Centre Ljubljana

Asset

Liraglutide

Subcutaneous · GLP-1 agonist

Listed sites

Recruiting sites

—

Enrollment

actual

Study population

Obesity / overweight, PCOS, Reproductive / infertility

Key I/E criterion

•Female

Primary endpoints

•IVF pregnancy rates•BMI, change•Cumulative pregnancy rates

Identifiers

Registered as

NCT IDNCT03353948

Org study IDObese PCOS IVF

Timeline

Milestones

Study start2014-09-01actual

Primary completion2016-05-31actual

Study completion2016-09-01actual

Study first posted2017-11-27actual

Last update posted2017-11-27actual

Assets

Investigational agents

Liraglutide

Study populations

Who this study enrolls

Obesity / overweightPCOSReproductive / infertility

Eligibility

Who can enroll

Minimum age18 Years

Maximum age37 Years

SexFemale

Healthy volunteersNot accepted

Inclusion criteria

•18 years old to 38 years old

•polycystic ovary syndrome (rotterdam criteria)

•BMI of 30 kg/m² or higher

•Infertility

•Before IVF

Exclusion criteria

•type 1 or type 2 diabetes mellitus

–history of carcinoma

–Cushing's syndrome or congenital (non-classic) adrenal hyperplasia

–personal or family history of MEN 2

–significant cardiovascular, kidney or hepatic disease

–the use of medications known or suspected to affect reproductive or metabolic functions

–the use of statins, within 90 days prior to study entry no other ovarian pathology normal male semen

Endpoints (10)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Other clinical outcomes

Glycemic / diabetes

Weight & body composition

Other (unclassified)

Weight & body composition

1 endpoint

Primary/protocol endpoint

BMI

Time frame:Patient's BMI was measured at the beginning and every four weeks during 12 weeks of clinical trial. ]

BMI, change

change from baseline, improvement

Glycemic / diabetes

2 endpoints

Other/protocol endpoint

The other outcomes was changes changes in fasting concentrations of glucose

Time frame:Patient's fasting blood was drawn at the beginning and every four weeks during the 12 weeks of clinical trial.

Fasting glucose, change

change from baseline, improvement

LOINC 1558-6

Other/protocol endpoint

The other outcomes was changes changes in fasting concentrations of insulin

Time frame:Patient's fasting blood was drawn at the beginning and every four weeks during the 12 weeks of clinical trial.

change from baseline, improvement

Other clinical outcomes

6 endpoints

Primary/protocol endpoint

IVF pregnancy rates

Time frame:14 days

threshold achievement, improvement

Primary/protocol endpoint

Cumulative pregnancy rates

Time frame:The pregnancies were collected by phone interview after one year

event count, event

Secondary/protocol endpoint

Oocyte nuclear maturation

Time frame:2 days

event count, descriptive

Secondary/protocol endpoint

Embryo quality

Time frame:6 days

descriptive

Other/protocol endpoint

Other outcome was change in blood concentration of testosterone

Time frame:Patient's fasting blood was drawn at the beginning and every four weeks during the 12 weeks of clinical trial. ]

Androgen, change

change from baseline, improvement

Other/protocol endpoint

Other outcome was change in blood concentration in androstenedione.

Time frame:Patient's fasting blood was drawn at the beginning and every four weeks during the 12 weeks of clinical trial.

Androgen, change

change from baseline, improvement

Other (unclassified)

1 endpoint

Other/protocol endpoint/low confidence

Other outcome was change in blood concentrations of SHBG (sex hormone-binding globulin).

Time frame:Patient's fasting blood was drawn at the beginning and every four weeks during the 12 weeks of clinical trial. ]

change from baseline, improvement

Publications (2)

Bibliography

Records linked to this trial through ClinicalTrials.gov references, PubMed NCT search, and curated study seeds. 'Canonical' marks design/result papers; others are registry references or candidates.

Registry references + supporting bibliography

The Endometrial Transcriptome of Metabolic and Inflammatory Pathways During the Window of Implantation Is Deranged in Infertile Obese Polycystic Ovarian Syndrome Women.
Metabolic syndrome and related disorders2022 Sep (month)PMID35834645doi:10.1089/met.2021.0149via clinicaltrials gov reference derived + pubmed nct search
Short-term combined treatment with liraglutide and metformin leads to significant weight loss in obese women with polycystic ovary syndrome and previous poor response to metformin.
European journal of endocrinology2014 Mar (month)PMID24362411doi:10.1530/EJE-13-0797via CT.gov background

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2

Snapshot dateJuly 1, 2026

Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)

Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 1, 2026 snapshot.